AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund. Schroer added that AbbVie's purchase of Pharmacyclics will also fill gaps in the company's pipeline. He is also bullish on Vertex, saying the company's new cystic fibrosis combination therapy will substantially expand its treatable base, adding the company has a good chance of being acquired in this heightened M&A environment. Finally, Schroer is bullish on Biogen shares due to its pipeline and potential earnings growth.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.